Fig. 2From: Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysisCurves for cumulative incidence function for each histologic subtypeBack to article page